Award
NIH Reporter #PA-20-185
Selective Inhibition of GRP 94 to Treat Ocular Hypertension and Glaucoma
Recipient
University of Notre Dame
Award Amount
$591,767.00
Ceiling
$591,767.00
Awarded
July 27, 2026
Identifier
PA-20-185
Research grant awarded to University of Notre Dame to develop isoform-selective inhibitors of Grp94 for treating glaucoma, focusing on reducing protein aggregation and restoring intraocular pressure.
Description
The project aims to optimize and elucidate the mechanism by which isoform-selective inhibitors of Grp94 can be used for the potential treatment of glaucoma, specifically targeting primary open-angle glaucoma (POAG) and steroid-induced glaucoma. The research focuses on the role of Grp94 in modulating ER stress and protein folding, with the goal of developing therapeutics that reduce protein aggregation and restore intraocular pressure.